RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
Comparison of office and ambulatory blood pressure measurements to assess the angiotensin II receptor antagonist eprosartan.
BACKGROUND : To determine the efficacy and dose-response of the new angiotensin II receptor antagonist eprosartan , we conducted a 4-week , double-blind , r and omized , multicenter study in 114 men with essential hypertension using trough clinic and ambulatory blood pressure measurements . METHODS : Patients were included if the seated diastolic blood pressure was between 95 and 115 mmHg inclusive and 0 - 12 h diastolic blood pressure was at least 87 mmHg . The effects of twice daily eprosartan at 50 , 100 , 150 and 200 mg were compared with those of placebo . RESULTS : At trough , the clinic diastolic blood pressure was reduced significantly only by the 200 mg dose compared with placebo ( mean placebo-subtracted change -6.0 mmHg , 95 % confidence intervals -10.5 , -1.5 , P = 0.001 ) . In contrast , the 12 h mean reduction in diastolic blood pressure was significant for both the 150 mg dose ( mean change -5.3 mmHg , 95 % confidence intervals -10.2 , -0.1 , P = 0.0075 ) and the 200 mg dose ( mean change -5.5 mmHg , 95 % confidence intervals -10.3 , -0.6 , P = 0.0049 ) . Similar trends were observed for the systolic pressure and mean changes in 24 h pressures .  Eprosartan significantly reduced adjusted mean daytime ( 0 - 12 h after dose ) diastolic ambulatory pressure linearly with dose . CONCLUSION : These data demonstrate increased sensitivity of the ambulatory blood pressure over the research clinic blood pressure in evaluating the efficacy of the new antihypertensive agent eprosartan . Additionally , these findings demonstrate that higher doses of this drug will be necessary in future studies
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .